Building on AE’s documented PI3K/Akt inhibitory effects in other cancers (Peng et al., 2022; Zhu et al., 2023), we hypothesize that AE suppresses NPC progression by targeting LncRNA D63785 to attenuate PI3K/Akt/mTOR pathway activation. Here, AKT1 is linked to nasopharyngeal carcinoma.